1. Luciferase-induced immune activation prevents orthotopic K7M2luc osteosarcoma establishment in BALB/c miceSaša Kupčič, Urška Kamenšek, Maja Čemažar, Urša Lampreht Tratar, 2026, izvirni znanstveni članek Povzetek: Background. Use of murine orthotopic tumor models dictates utilization of luciferase-expressing cells for in vivo biolu-minescence imaging. However, luciferase may trigger immune responses that impair tumor establishment.Materials and methods. We transduced K7M2 cells wild-type (wt) with luciferase gene and evaluated their growth in vitro. We then implanted cells orthotopically in BALB/c mice and upon unsuccessful tumor establishment assessed systemical and local mechanism for tumor growth suppression.Results. All investigated cell lines had a comparative doubling time in vitro at 24 and 48h. Despite that, K7M2luc E5 differed from K7M2luc A7 and K7M2 wt by having a much higher proliferation rate at 72h (35x, 15x and 17x). In vivo, both luciferase-expressing cell lines failed to establish tumors, whereas K7M2 wt had a 100% success rate. To investi-gate the underlying mechanism, we assessed systemic and local cell-mediated immunity. Mice in groups K7M2luc A7 and K7M2luc E5 had a higher fold change (5 ± 0.8 and 6 ± 1.05) of GrB secreting splenocytes than naïve mice (1 ± 0.2). In the bone microenvironment, luciferase groups exhibited elevated numbers of GrB-secreting cells and CD8+T cells relative to K7M2 wt and naïve mice.Conclusions. These findings indicate that luciferase activates cytotoxic T-cell responses capable of eliminating im-planted cells. Tumor establishment was restored in immunodeficient mice lacking CD8+ cells, confirming the immune-mediated rejection.
Ključne besede: mouse orthotopic tumor, luciferase, bioluminescence, osteosarcoma
Objavljeno v DiRROS: 09.09.2026; Ogledov: 60; Prenosov: 37
 Celotno besedilo (1,95 MB) |
2. Non-thermal ablation and drug delivery by electroporation : expanding current indications beyond cancer and cardiac treatmentDamijan Miklavčič, Helena Cindrič, Rafael V. Davalos, Frederic Deschamps, Julie Gehl, Bor Kos, Peter Kramar, Dimitrij Kuhelj, Martijn R. Meijerink, Declan M. Soden, Miha Štabuc, Gregor Serša, 2026, pregledni znanstveni članek Povzetek: Background. Electroporation-Based Treatments and Therapies (EBTTs) – electrochemotherapy, irreversible electroporation, pulsed field ablation, and gene electro-transfer – use short, high-voltage electric pulses to permeabilize cell membranes, enabling non-thermal tissue ablation and enhanced local drug delivery. Although EBTTs have been used clinically for over three decades, primarily in oncology, their adoption remains limited compared to thermal ablation modalities. In contrast, cardiac pulsed field ablation (PFA) has seen rapid adoption since the first FDA device approval in December 2023. Conclusions. This expert opinion paper reviews the current clinical landscape of EBTTs in oncology and cardiac arrhythmia treatments, and focuses on emerging non-oncological and non-cardiac applications, including endoscopic pulsed electric field therapy for type 2 diabetes, bronchial rheoplasty for chronic bronchitis, bleomycin electrosclerotherapy for vascular malformations, nanosecond PFA for benign thyroid nodules, and electroporation-mediated gene delivery – and identifies key barriers to wider adoption: insufficient randomized evidence, lack of validated treatment planning tools, fragmented reimbursement, and limited standardization. We outline measures to facilitate clinical translation.
Objavljeno v DiRROS: 02.09.2026; Ogledov: 158; Prenosov: 95
Celotno besedilo (5,69 MB)
Gradivo ima več datotek! Več... |
3. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases : a single-institution experienceGašper Pilko, Rok Petrič, 2026, izvirni znanstveni članek Povzetek: Peritoneal metastases (PM) from colorectal cancer are associated with poor prognosis. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has been proposed for selected patients, although its role remains debated. This study evaluates the efficacy and safety of CRS plus HIPEC in a single institution. Patients and methods. This retrospective study included patients with colorectal PM treated with CRS and HIPEC between 2009 and 2024. Preoperative staging involved CT and/or MRI, and all cases were discussed in a multidisciplinary team. Disease burden was assessed using the Peritoneal Cancer Index (PCI), and completeness of cytoreduction (CC score) was recorded. HIPEC was performed with oxaliplatin (360 mg/m² at 42°C for 90 minutes). Overall survival (OS) was the primary endpoint; disease-free survival (DFS) and morbidity were secondary endpoints. Results. Fifty patients (mean age 54 years) were included. Complete cytoreduction (CC-0/1) was achieved in 88% of cases, with a median PCI of 8.33. Severe complications occurred in 18% of patients, with no 30-day mortality. After a median follow-up of 34 months, median OS was 49 months; 1- and 5-year OS rates were 96% and 54%, respectively. Median DFS was 14 months. PCI, CC score, and prior surgical score (PSS) were associated with OS on univariate analysis, while PCI and CC score remained independent prognostic factors. Conclusions. CRS plus HIPEC is a feasible and effective treatment for selected patients with colorectal PM, with acceptable morbidity. Low PCI and complete cytoreduction are key predictors of improved survival.
Ključne besede: colorectal cancer, peritoneal metastases, cytoreductive surgery, HIPEC
Objavljeno v DiRROS: 02.09.2026; Ogledov: 146; Prenosov: 64
Celotno besedilo (5,69 MB) |
4. Onkološka epidemiologija včeraj, danes, jutriVesna Zadnik, 2026, objavljeni strokovni prispevek na konferenci Povzetek: Onkološka epidemiologija proučuje pogostost, razporeditev in vzroke za nastanek raka v populaciji ter s pomočjo sistematičnega zbiranja, povezovanja in interpretacije podatkov podpira spremljanje bremena raka, preživetja bolnikov ter načrtovanje javnozdravstvenih ukrepov. V prispevku ovrednotimo napovedi o razvoju stroke, zapisane ob Onkološkem vikendu 2016, ter nakažemo ključne usmeritve za prihodnje desetletje. Ugotavljamo, da so se uresničile napovedi o vse večjem povezovanju podatkovnih virov, večjem pomenu interdisciplinarnosti in natančnejšem vrednotenju dejavnikov tveganja. Pomembno smo napredovali pri povezovanju registrov in drugih zbirk, čeprav enkratni zajem podatkov in njihova popolna spletna izmenjava še nista v celoti vzpostavljena. Nismo pa predvideli pomena kliničnih registrov, spletnih zdravstvenih portalov, spremljanja kakovosti obravnave ter kakovosti življenja po raku. Prav tako nismo predvideli tako hitrega razvoja umetne inteligence, ki bo skupaj z digitalnimi zdravstvenimi sistemi pomembno zaznamovala prihodnji razvoj. V prihodnje pričakujemo večje povezovanje populacijskih in kliničnih podatkov, večji poudarek na spremljanju preživelih po raku, vključevanje PROMs ter okrepljeno vlogo epidemiologije pri vrednotenju učinkovitosti zdravstvenega sistema in podpori odločanju.
Ključne besede: onkologija, presejalni programi, epidemiologija, obvladovanje raka
Objavljeno v DiRROS: 01.09.2026; Ogledov: 173; Prenosov: 54
Celotno besedilo (238,37 KB) |
5. |
6. |
7. |
8. |
9. |
10. |
